An observational study in Pulmonary Disease and Asthma, sponsored by Taichung Veterans General Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Taichung Veterans General Hospital · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Asthma with a site in Taiwan — 13 open to participants now, 18 under way, 4 of them phase 3. Asthma · Taiwan.
Among the 88 studies in Asthma with a site in Taiwan, this one is the 4th largest by planned enrollment of the 16 observational ones that give a count, is one of 9 that started in 2023, is one of 16 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 79th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →13 of the 88 studies in Asthma with a site in Taiwan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Taiwan, Argentina, France and 7 more countries
Ages 12–17
AstraZeneca · Sites in Taiwan, Argentina, Egypt and 4 more countries
Ages 18+
Pfizer · Sites in Taiwan, United States, Argentina and 12 more countries
Ages 18–75
AstraZeneca · Sites in Taiwan, United States, Argentina and 18 more countries
Ages 18–75
GlaxoSmithKline · Sites in Taiwan, United States, Belgium and 9 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 274 across the 72 interventional studies, 225 across the 16 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 88 have an industry lead sponsor. The 10 most frequent:
Taichung Veterans General Hospital is the lead sponsor of 176 studies on the registry; 38 are open to participants now.
Taichung Veterans General Hospital has 2 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
6 of the studies in Asthma with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT06932263AstraZenecaDose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | 2027-06-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 88 studies in Asthma with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan.
The goal of this observational study is to discover the real-world effectiveness, the impact of initiating, switching of biologics, and the possible prediction factors for selecting the best treatment option for patients.
The main question[s] it aims to answer are:
Participants who are treated either with omalizumab, mepolizumab, benralizumab dupilzumab or Tezepelumab after January 1, 2020 will be included in the study.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
This study's planned enrollment of 500 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Browse Asthma studies →Taichung Veterans General Hospital is the lead sponsor of 176 studies on the registry; 38 are open to participants now.
Compared within Asthma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Severe Asthma Patient
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Severe asthma patients who are treated with omalizumab after January 1, 2020.
Biological: Biological Treatment for severe asthma patients
Severe asthma patients who are treated with mepolizumab after January 1, 2020.
Biological: Biological Treatment for severe asthma patients
Severe asthma patients who are treated with benralizumab after January 1, 2020.
Biological: Biological Treatment for severe asthma patients
Severe asthma patients who are treated with dupilzumab after January 1, 2020.
Biological: Biological Treatment for severe asthma patients
Severe asthma patients who are treated with Tezepelumab after January 1, 2020.
Biological: Biological Treatment for severe asthma patients
Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance
Also known as: Omalizumab, Mepolizumab, Benralizumab, Dupilzumab, Tezepelumab
Status of Asthma Control
Mean change in Asthma Control Test score after biologic initiation.
Time frame: 6 months
Status of Asthma exacerbations
Annual frequency of exacerbations after biologic initiation.
Time frame: 6 months
Reduction of daily oral corticosteriod dose
Percentage of daily oral corticosteroids dose reduction after biologic initiation.
Time frame: 6 months
Change of Pre-BD FEV1 (%pred)
Measure the change of Pre-BD FEV1 (%pred) after biologic initiation. FVC (L) FEV1(L)
Time frame: 6 months
Disease Prognosis
1. Describe the Cross-sectional phenotypic or pathophysiological (endotype) characteristics of poor asthma control. 2. Describe the natural history, intervention responsiveness and long-term prognosis of severe asthma.
Time frame: 6 months
Mortality
Define the mortality rate of the study cohort
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Feb 2043, 231 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 231 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taichung Veterans General Hospital →